20.500.12556/DiRROS-29784 Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs Objective: To determine the dynamics of serum levels of TNF-α in patients with juvenile idiopathic arthritis (JIA) treated with anti-TNF-α biological drugs and investigate their association with the disease activity. Methods: We conducted a single-centre, observational cohort study in 98 patients with JIA (30 boys, 68 girls, mean age 11.3 years) treated with anti-TNF-α biological drugs. Clinical examinations and laboratory assessments of serum levels of TNF-α were performed before starting therapy with biological drug and at 6-month intervals afterwards up to 2.5 years. Results: The analysis of serum levels of TNF-α in relation to the disease activity states showed the highest mean serum levels of TNF-α in patients on etanercept who had low disease activity states and in patients on adalimumab who had inactive disease. The correlation analysis in patients with JIA treated with etanercept or adalimumab showed a weak negative correlation between the serum levels of TNF-α and JADAS10 scores (p = 0.007), (r = - 0.177). Conclusion: The assessment of serum levels of TNF-α in children with JIA during treatment with etanercept or adalimumab is not a reliable biomarker of disease activity or immunological remission. Longitudinal measurement of TNF-α has no added clinical value in patients with JIA treated with anti-TNF-α biological drugs. Key Points • There is limited evidence regarding the effect of anti-TNF therapy on serum concentrations of TNF-α in patients with juvenile idiopathic arthritis • Our study showed an increase in the serum level of TNF-α after the initiation of therapy with either etanercept or adalimumab, which was more significant in patients with inactive or low disease activity • Serum TNF-α is most likely not biologically active during therapy with TNF-α inhibitors and therefore not a reliable biomarker of disease activity or immunological remission in patients with juvenile idiopathic arthritis adalimumab cytokines etanercept juvenile idiopathic arthritis tumour necrosis factor-alpha true false true Angleški jezik Ni določen Neznano 2026-06-05 09:47:26 2026-06-05 09:47:27 2026-06-06 03:58:31 0000-00-00 00:00:00 2024 0 0 str. 2287-2293 iss. 7 Vol. 43 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 0770-3198 10.1007/s10067-024-07012-4 203660291 RAZ_Morozova_Nataliia_2024.pdf RAZ_Morozova_Nataliia_2024.pdf 1 2D19D559F428C2EDCA38BD48C0857FDA 3c83a495aba4ec43e45616a66102f3a207625119627f3abbe1f0725cb84498bc ee816ac8-60b2-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44773 Univerzitetni klinični center Ljubljana 0 0 0